Trial Profile

TARGETED RADIOTHERAPY WITH CONDITIONING PRIOR TO HAEMATOPOIETIC STEM CELL TRANSPLANTATION - A randomised phase II clinical trial using targeted radiotherapy delivered by an Yttrium 90 radiolabelled anti-CD66 monclonal antibody with high dose melphalan compared to melphalan alone, prior to autologous stem cell transplantation for multiple myeloma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Dec 2020 Biomarkers information updated
31 Oct 2013 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
04 Oct 2012 Accrual to date is 27% according to United Kingdom Clinical Research Network.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com